• FDA Approves Imbruvica Plus Rituximab americanpharmaceuticalreview
    August 28, 2018
    Janssen Pharmaceutical announced the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia (WM), a rare blood cancer.
PharmaSources Customer Service